15Nov 2023
Dapagliflozin Study Shows Initial eGFR Decline Unrelated to Cardiovascular or Kidney Risks in Heart Failure Patients

Dapagliflozin Study Shows Initial eGFR Decline Unrelated to Cardiovascular or Kidney Risks in Heart Failure Patients

In a prespecified analysis of the DELIVER trial, a study examined the impact of initiating dapagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), on estimated glomerular filtration rate (eGFR) in heart failure patients. The study from August 2018 to March 2022 included 5788 participants with preserved or mildly reduced ejection fraction. Results showed that dapagliflozin induced an initial eGFR decline in 40% of patients, but this was not associated with increased cardiovascular or kidney risks. The findings support the recommendation not to interrupt SGLT2i treatment based on initial eGFR changes. The study underscores the safety of continuing SGLT2i therapy in heart failure patients.

  • #cardiology

Like

Save

Share